U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906497) titled 'Lebrikizumab in Moderate-to-severe Atopic Dermatitis' on March 25.
Brief Summary: This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: lebrikizumab
Patients will receive lebrikizumab with a 500 mg loading dose administered subcutaneously at baseline and Week 2 followed by 250 mg every 2 weeks until Week 24.
At week ...